Exelixis’s Cabometyx Plus Tecentriq Disappoints In Lung Cancer

Earlier Data Showed Better Results For Roche Pairing

 
• By Joseph Haas
Lung Cancer
Updated data put Cabometyx's utility in lung cancer in doubt

More from Clinical Trials

More from R&D